Chronic lead exposure alters dopaminergic mechanisms in rat pituitary.
The effect of chronic lead treatment on pituitary dopamine (DA) D2 receptors was studied by measuring (-)sulpiride-displaceable [3H]spiroperidol-binding and DA-inhibited adenylate cyclase. Receptor number was reduced in lead-exposed animals and bromocriptine was less able to inhibit cyclase activity in pituitary homogenates. In addition, the capacity of DA to inhibit the VIP-stimulated cAMP formation was decreased.
D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D001971:Bromocriptine / Q000494:pharmacology; D000242:Cyclic AMP / Q000096:biosynthesis; D004298:Dopamine / Q000494:pharmacology; D005260:Female; D007854:Lead / Q000633:toxicity*; D010902:Pituitary Gland / Q000187:drug effects* / Q000201:enzymology; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism; D013134:Spiperone / Q000378:metabolism; D013469:Sulpiride / Q000378:metabolism
D000067956:Adenylyl Cyclase Inhibitors; D011954:Receptors, Dopamine; D007854:Lead; D001971:Bromocriptine; D013134:Spiperone; D013469:Sulpiride; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D004298:Dopamine